Preparation and in vitro evaluation of solid lipid nanoparticle formülations containing carvedilol

The aim of this thesis study is to prepare orally applicable solid lipid nanoparticle (SLN) delivery system, to add the carvedilol which is a drug substance proven clinical effetiveness after heart failure (HF) and mycordial infarction (MI) to the system, to improve of new drug delivery system which is showing controlled release and to do in vitro release studies. Carvedilol is an α1, β1 and β2 adrenergic receptor with an adrenergic blocking properties. Carvedilol has been shown that the organ protective effects. Carvedilol eliminates an effective antioxidant and reactive oxygen radicals. Carvedilol is racemic, and both R (+) and S (-) isomer of the α1 adrenergic receptor blockade and has antioxidant properties. Carvedilol has antiproliferative effects on human vascular smooth muscle cells. Mild or severe heart failure improves ventricular function in patients that have been proven in studies to reduce mortality and morbidity. It must therefore be considered as the standard treatment option for patients with heart failure. In this study, SLN system containing carvedilol was developed. In the SLN system, Dynasan® 114 was used as the solid lipid, while Tween® 80 was used as the surfactant. Lipid structures of SLNs were verified to be unchanged by the X-ray diffraction (XRD), differential scanning calorimetry (DSC), infrared (IR) and nuclear magnetic resonance (NMR) analyses.